In vitro selective concentrations of cefepime and ceftazidime for AmpC β-lactamase hyperproducer Enterobacter cloacae variants Maria-Cristina Negri,

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents

Pharmacokinetics in vivo and pharmacodynamics ex vivo/in vitro of meropenem and cefpirome in the Yucatan micropig model: continuous infusion versus intermittent.

R. Cantón, A. Novais, A. Valverde, E. Machado, L. Peixe, F. Baquero, T

Defining an extended-spectrum β-lactamase

Approach to diagnosis of infective endocarditis

Interaction of insulin and Burkholderia cepacia

Herpes zoster in non-hospitalized children

Clinical characteristics of Haemophilus influenzae meningitis in Denmark in the post- vaccination era T.I. Pedersen, M. Howitz, C. Østergaard Clinical.

Defining an extended-spectrum β-lactamase

Inducible β-lactamase-mediated resistance to third-generation cephalosporins Ronald N Jones, Fernando Baquero, Gaetano Privitera, Matsuhisa Inoue, Bernd.

Hydatid disease Clinical Microbiology and Infection

Current patterns and evolution of antibiotic resistance among bacterial pathogens involved in acute otitis media Fernando Baquero, Rafael Cantón, Fernando.

Link between intracellular pathogens and cardiovascular diseases

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia.

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species Jacques Dubois, Claude St-Pierre Clinical.

Alasdair P. MacGowan, Caroline Rynn, Mandy Wootton, Karen E. Bowker, H

Structure of grepafloxacin relative to activity and safety profile

Vector control: a cornerstone in the malaria elimination campaign

Evaluation of antibacterial activity of cefodizime, ceftriaxone and cefonicid in Klebsiella pneumoniae-infected guinea pigs Lorenzo Drago, Barbara Mombelli,

The role of fourth-generation cephalosporins in the treatment of infections caused by penicillin-resistant streptococci Keith Klugman, Fred Goldstein,

Fourth-generation cephalosporins: a review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility Javier Garau, Walter Wilson,

C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins

Multicenter study of the in vitro activity of cefepime in comparison with five other broad- spectrum antibiotics against clinical isolates of Gram-positive.

Mechanisms of quinolone resistance in clinical isolates of Enterobacter cloacae Apostolos Georgopoulos, Robert Schein, Astrid Buxbaum, Susan Tzotzos,

Training for the infectious diseases speciality in Norway

The antibacterial effects of ciprofloxacin and trovafloxacin against Streptococcus pneumoniae in an in vitro dynamic model Matthew O'Brien, Thuy Quach,

Cephalosporins: a pharmacological update

Epidemiology of opportunistic infections in AIDS patients

Laboratory diagnosis and biosafety issues of biological warfare agents

Sepsis and neutropenia induced by clozapine

C. Varela, A. Oliver, T.M. Coque, F. Baquero, R. Canton

A comparative study of the in vitro activity of meropenem and representatives of the major classes of broad-spectrum antibiotics J. Moira Greenhalgh,

Uncommon opportunistic fungi: new nosocomial threats

In vitro selection of antibiotic resistance in Pseudomonas aeruginosa

Isolation rate, T-serotyping and susceptibility to antibiotics of Group A Streptococcus from pediatric infections in Athens* M. Kanellopoulou, A. Makri,

Laboratory diagnosis of Clostridium difficile disease

W.A. Craig Clinical Microbiology and Infection

Recent developments in staphylococcal scalded skin syndrome

S8 – S47 and O50 – O440 Clinical Microbiology and Infection

Pathogenesis of catheter-related infections: lessons for new designs

Community-acquired pneumonia: epidemiologic and clinical consideration

Jacques Sirot Clinical Microbiology and Infection

Fibronectin concentrations in catheter sepsis

Definition of the Clinical Antibacterial Spectrum of Activity

Clinical infection services—the Leiden experience

Ethan Rubinstein, Itzhak Levy Clinical Microbiology and Infection

Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party Dilip Nathwani, Christopher Conlon Clinical.

R. Cantón, A. Novais, A. Valverde, E. Machado, L. Peixe, F. Baquero, T

Clinical Microbiology and Infection

The influence of protein binding on the antibacterial activity of faropenem against Haemophilus influenzae I. Gustafsson, O. Cars Clinical Microbiology.

Empiric therapy of bacterial infections in severe neutropenia

W. Eugene Sanders, Christine C. Sanders

Overview of cefixime use in community-acquired infections

The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model Alasdair P. MacGowan,

Sanford Chodosh Clinical Microbiology and Infection

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Abstracts Clinical Microbiology and Infection

New oral cephalosporins in pediatric community-acquired infections

Carratalà J. Clinical Microbiology and Infection

J.L. Balcázar Clinical Microbiology and Infection

Clinical microbiological case: thermointolerant microorganism growth in blood cultures and catheter tip M. Blasco-Navalpotro, M. Jordán, J.J. Camarena,

Typing of Clostridium difficile

G. Kahlmeter Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party Dilip Nathwani, Christopher Conlon Clinical.

Fernando Baquero, John F

The future of diagnostic bacteriology

Presentation transcript:

In vitro selective concentrations of cefepime and ceftazidime for AmpC β-lactamase hyperproducer Enterobacter cloacae variants Maria-Cristina Negri, Fernando Baquero Clinical Microbiology and Infection Volume 5, Pages S25-S28 (March 1999) DOI: 10.1111/j.1469-0691.1999.tb00721.x Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Proportion of wild-type E. cloacae RYC12991 strain (white bars), and constitutively derepressed variants hyperproducing AmpC (black bars), after a 4-h challenge with different concentrations of ceftazidime (upper part) or cefepime (lower part), followed by a 24-h period of growth in antibiotic-free medium. Clinical Microbiology and Infection 1999 5, S25-S28DOI: (10.1111/j.1469-0691.1999.tb00721.x) Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Expected serum levels of ceftazidime ( ) or cefepime ( ) after a single intravenous administration of 1 g (A) or 2 g (B). The frames show the time periods where the concentrations may be selective for the constitutively AmpC β-lactamase hyperproducer E. cloacae RYC12991 strain. Clinical Microbiology and Infection 1999 5, S25-S28DOI: (10.1111/j.1469-0691.1999.tb00721.x) Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions